Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Sequestration Will Harm Beneficiary Access Despite 2% Limit, Rep. Burgess Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Rep. Burgess sees little congressional enthusiasm for trying to avoid the across-the-board federal budget cuts, slated for March 1, as further budget battles loom on the horizon.

You may also be interested in...

Part D Mandatory Rebates Included In Speaker Boehner’s “Fiscal Cliff” Offer

House Speaker John Boehner made an offer to President Obama Dec. 3 to base a resolution to the looming fiscal cliff on a proposal by the president’s deficit commission headed by Erskine Bowles and Alan Simpson, a proposal that included a mandatory rebate on drugs used in Medicare Part D.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts